Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention (Q35172201)

6 August 2017

1 reference

title

Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention (English)

1 reference

6 August 2017

0 references

1

Pier Luigi Meroni

1 reference

6 August 2017

Elena Raschi

2

1 reference

PubMed ID

12849059

6 August 2017

Cinzia Testoni

series ordinal

3

1 reference

6 August 2017

1 February 2002

1 reference

6 August 2017

1 reference

6 August 2017

1

1 reference

6 August 2017

1-2

1 reference

6 August 2017

55-60

1 reference

Antiphospholipid antibodies and the endothelium

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Immune Recognition at the Maternal‐Fetal Interface: Overview

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Purification and characterization of an endothelial cell-viability maintaining factor from fetal bovine serum

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Pathogenic mechanisms mediating antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Endothelial cell procoagulant properties and the host response

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Experimental thrombosis and antiphospholipid antibodies: new insights

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Pleiotropic effects of statins.

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Levels of soluble cell adhesion molecules in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1568-9972%2801%2900014-3

7 January 2021

10.1016/S1568-9972(01)00014-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12849059